Meital Ryan

Title: Meital Ryan: Innovator in Hepatocellular Carcinoma Prognosis

Introduction

Meital Ryan is a prominent inventor based in Mountain View, CA (US). She has made significant contributions to the field of cancer research, particularly in the prognosis of hepatocellular carcinoma (HCC). Her innovative work focuses on utilizing genomic analysis to improve patient outcomes.

Latest Patents

Meital Ryan holds a patent titled "Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis." This patent describes a groundbreaking approach that identifies a 12-gene signature, which includes both up-regulated and down-regulated genes. This signature is highly predictive of metastasis and overall survival in human patients with HCC. The patent also outlines methods for determining the metastatic status of a patient's hepatocellular carcinoma by analyzing gene expression profiles from carcinoma samples.

Career Highlights

Meital Ryan is affiliated with Leland Stanford Junior University, where she conducts her research and develops her innovative methodologies. Her work has the potential to significantly impact the way hepatocellular carcinoma is diagnosed and treated, ultimately improving patient care.

Collaborations

Meital has collaborated with notable colleagues in her field, including Robert Tibshirani and Dean W. Felsher. These collaborations have further enhanced her research and contributed to the advancement of cancer prognosis methodologies.

Conclusion

Meital Ryan is a trailblazer in the field of cancer research, with her innovative patent offering new hope for patients with hepatocellular carcinoma. Her work exemplifies the importance of genomic analysis in improving cancer prognosis and treatment strategies.